Evidence map›Paper›PMID 31183633›Full record

ArticleMedical oncology (Northwood, London, England)2019

Forced expression of NR4A3 induced the differentiation of human neuroblastoma-derived NB1 cells.

Takayuki Hirano, Eri Nagasaki-Maeoka, Yoshiaki Ishizuka, Atsushi Takatori, Yosuke Watanabe, Reina Hoshi, Shinsuke Yoshizawa, Hiroyuki Kawashima, Shota Uekusa, Kiminobu Sugito and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Takayuki HiranoDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Eri Nagasaki-MaeokaDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Yoshiaki IshizukaDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Atsushi TakatoriDivision of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, 260-8717, Japan.
Yosuke WatanabeDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Reina HoshiDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Shinsuke YoshizawaDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Hiroyuki KawashimaDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Shota UekusaDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Kiminobu SugitoDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Shuichiro UeharaDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Noboru FukudaDivision of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Hiroki NagaseLaboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, 260-8717, Japan.
Tadateru TakayamaDivision of General Medicine, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi, Tokyo, 173-8610, Japan.
Masayoshi SomaDivision of General Medicine, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi, Tokyo, 173-8610, Japan.
Tsugumichi KoshinagaDepartment of Pediatric Surgery, Nihon University School of Medicine, Itabashi, Tokyo, 173-8610, Japan.
Kyoko FujiwaraDivision of General Medicine, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi, Tokyo, 173-8610, Japan. fujiwara.kyoko@nihon-u.ac.jp.ORCID http://orcid.org/0000-0002-1751-7968
Nihon University · JPChiba Cancer Center · JP

Funding

MEXT Japan MEXT-Supported Program for the Strategic Research Foundation at Private Universities (2011-2015)
6 · The paper itself

Abstract

Nuclear receptor subfamily 4, group A, member 3 (NR4A3) is a member of the NR4A subgroup of orphan nuclear receptors, implicated in the regulation of diverse biological functions, including metabolism, angiogenesis, inflammation, cell proliferation, and apoptosis. Although many reports have suggested the involvement of NR4A3 in the development and/or progression of tumors, its role varies among tumor types. Previously, we reported that DNA hypomethylation at NR4A3 exon 3 is associated with lower survival rate of neuroblastoma (NB) patients. As hypomethylation of this region results in reduced expression of NR4A3, our observations suggested that NR4A3 functions as a tumor suppressor in NB. However, the exact mechanisms underlying its functions have not been clarified. In the present study, we analyzed public databases and showed that reduced NR4A3 expression was associated with shorter survival period of NB in two out of three datasets. An in vitro study revealed that forced expression of NR4A3 in human NB-derived cell line NB1 resulted in elongation of neurites along with overexpression of GAP43, one of the differentiation markers of NB. On the other hand, siRNA-mediated knockdown of NR4A3 suppressed the expression level of GAP43. Interestingly, the forced expression of NR4A3 induced only the GAP43 but not the other molecules involved in NB cell differentiation, such as MYCN, TRKA, and PHOX2B. These results indicated that NR4A3 directly activates the expression of GAP43 and induces differentiated phenotypes of NB cells, without affecting the upstream signals regulating GAP43 expression and NB differentiation.

Indexed as

Cell DifferentiationCell Line, TumorDisease ProgressionDNA-Binding ProteinsGAP-43 ProteinGene Knockdown TechniquesHumansNeuritesNeuroblastomaReceptors, SteroidReceptors, Thyroid HormoneRNA, Small InterferingUp-RegulationDNA-Binding ProteinsGAP-43 ProteinNR4A3 protein, humanReceptors, SteroidReceptors, Thyroid HormoneRNA, Small InterferingDifferentiationGAP43NeuroblastomaNR4A3

Identifiers

PMID31183633
OpenAlexW2950914596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.